This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.
Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
McCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.
Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.
Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.
Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.
Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.
In the Phase 2 MOUNTAINEER-01 study of patients with HER2-positive metastatic colorectal cancer who were chemo-refractory, the combination of tucatinib and trastuzumab showed an impressive response rate and disease control rate, and median duration of response up to 12 months; Dr. Ahn notes these results compare favorably to prior studies of dual HER2 inhibition, with MOUNTAINEER-01 showing higher response rates.
Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common form of bladder cancer, had been limited to cisplatin-based regimens and taxanes. This article explores the current and future outlooks for combination therapy with IOs in urothelial carcinoma.
The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
The panel shares some final thoughts on unmet needs and the future of CLL treatment.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.
Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.